Huadong Medicine
Huadong Medicine
Huadong Medicine is a comprehensive pharmaceuticals company.
Huadong Medicine, founded in March 1993 and headquartered in Hangzhou, is a comprehensive manufacturer and distributor of various types of antibiotics, proprietary Chinese medicines, and synthetic drugs. The founder is Lu Liang. Listed on the Shenzhen Stock Exchange on January 27, 2020, the company's major shareholders are China Grand Enterprises and Hangzhou Huadong Medicine. The direct and indirect competitors of Huadong Medicine include Hengrui Medicine, Humanwell Healthcare, Kelun Pharmaceutical.
- All
- News
- Analysis
- Research
Briefing Feb 07, 2023 12:11 PM
· Healthcare
ForLong Biotech Nets Over CNY 100 Mn in Series A
In-depth
Healthcare
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Oct 29, 2021 11:38 AM
Financial Associated Press, October 29 - a carbon monoxide poisoning accident occurred in an ironmaking plant in Xingtai, Hebei Province. Three people died after ineffective rescue.
Healthcare
Dynamic Biosystems Snags Nearly CNY 100 Mn in Series A+
Dynamic Biosystems is a single cell and space multi-omics technology platform enterprise. The company focuses on exploring the huge potential in the fields of precision medicine of tumor, eugenics and fertility, and drug discovery, and is committed to promoting precision medicine to the era of single cell and space omics, helping life science and clinical medicine.
Feb 06, 2023 07:25 PM
Insight
Healthcare
Opportunities and Challenges Hidden in the CGT Industry in China
CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.
Jan 17, 2023 05:48 PM
Briefing Jul 06, 2021 10:41 AM
· Healthcare
Yimei concept stocks all weakened, Aoyuan Meigu closed down
See more
